TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Solasia Pharma KK ( (JP:4597) ) is now available.
Solasia Pharma K.K. reported its consolidated financial results for the first quarter of the fiscal year ending December 31, 2025, and provided updates on its major pipeline products. The company has faced a decline in sales of Sancuso in China due to shipment constraints following a manufacturing facility transfer. Meanwhile, DARVIAS, used for treating peripheral T-cell lymphoma, has seen progress with marketing rights out-licensed in Japan and South America, with ongoing regulatory approval processes in countries like Colombia and Peru.
More about Solasia Pharma KK
Solasia Pharma K.K. operates in the pharmaceutical industry, focusing on the development and commercialization of oncology treatments. The company is involved in the production of products like Sancuso, a transdermal delivery system for chemotherapy-induced nausea, and DARVIAS, an organic arsenic compound for treating peripheral T-cell lymphoma.
Average Trading Volume: 4,341,935
Technical Sentiment Signal: Sell
Current Market Cap: Yen7.02B
Learn more about 4597 stock on TipRanks’ Stock Analysis page.